Moderna faces long-term threat from NIH's universal vaccine initiative, Jefferies saysProactive Investors • 05/02/25
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026Benzinga • 05/01/25
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost CutsZacks Investment Research • 05/01/25
Moderna Reports First Quarter 2025 Financial Results and Provides Business UpdatesAccesswire • 05/01/25
Countdown to Moderna (MRNA) Q1 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 04/28/25
Is Moderna Stock A Sell After Massive Job Cuts Wrack U.S. Health Agencies?Investors Business Daily • 04/24/25
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 04/17/25
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.Investors Business Daily • 04/10/25
Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022The Motley Fool • 04/08/25